Navigation Links
Acquisition of Devices, Methods and Intellectual Property Support Leadership Position in Regenerative Therapies
Date:7/22/2013

AUSTIN, Texas, July 22, 2013 /PRNewswire/ -- On Wednesday, July 17th, Celling Biosciences made an asset acquisition of devices, proprietary methods and intellectual property from Orogen Biosciences.  Orogen, based out of Sarasota, Florida, was an early innovator in processing platelet rich plasma (PRP) and concentrating growth factors and cytokines to optimize the most effective and efficient methods for providing therapeutic treatments with a patient's own tissue.   With this acquisition, Celling is furthering its position as a leader of point of care, autologous cell therapy. 

Celling is focused on the three pillars of regenerative medicine (cells, substrates, and signals) known to enhance the environment for tissue repair, regeneration, and revascularization.  The devices (OPC and ACE) and methods from Orogen provide physicians with access to a patient's own growth factors and proteins to support the healing cascade.  There is a growing body of evidence in the literature of the role growth factors play in optimizing the healing in multiple pathologies across medicine.  The OPC device allows physicians to process autologous plasma at the point of care to deliver concentrated growth factors when compared to currently marketed options.  The ACE device is a unique technology that produces an enriched preparation of growth factors without the presence of white blood cells, red blood cells or platelets. 

Additionally, Celling has acquired methods and devices for delivering allogeneic products to the veterinary market. Based on the short and long term success of these products in treating horses and canines in soft tissue repair, Celling will be well positioned to penetrate the veterinary market which is leading human efforts into the emerging market of regenerative medicine.   

Celling has begun the process of transitioning Orogen revenues, opening a Florida office and launching devices to the market within the next quarter.  "We believe this is a unique opportunity for Celling to keep building our product and services portfolio in the autologous space.  We continue to expand our registered nurse service model across the country anticipating the orchestrated event in cell therapy between physicians and technology providers.  This acquisition is another step in adding sophistication to the process," says Kevin Dunworth, CEO and Founder of Celling Biosciences. We had a number of companies approach us about acquiring Orogen's intellectual property but we were waiting on the right fit both culturally and philosophically based on who we believed to be a leader in cell therapy innovation.  "We are extremely excited about this development and are confident that Celling Biosciences has the vision to create significant value in the regenerative medicine space," says Ryan Brandt, President of Orogen.  

About Celling Biosciences
Celling Biosciences is an Austin, Texas based company working closely with world leaders in academia, medicine, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine.  Celling's product-offering focuses on autologous cell therapy and the devices and services that compliment these procedures.  For more information please visit: www.cellingbiosciences.com.

Troy Wilford
twilford@cellingbiosciences.com


'/>"/>
SOURCE Celling Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. DTx to Introduce Data Acquisition Control & Robotic Instrument (DACRI) at Clinical Lab Expo in Houston, TX.
2. Techne Corporation Announces Acquisition Agreement
3. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
4. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
5. Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
6. bioRASI Completes Acquisition of Ukrainian CRO
7. BGI-Shenzhen Completes Acquisition of Complete Genomics
8. Biotrial, a Leading Provider of Drug Development Services, Has Completed its Acquisition of Warnex Bioanalytical Services Division
9. Inflamax Research Introduces Electronic Patient Data Acquisition Tablet™ (ePDAT)™ for Real-Time PRO Data Collection
10. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
11. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of ... board-certified in surgery and surgery of the hand by the National Board of ... to going above and beyond in his pursuit of providing the most comprehensive, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling arthritis since ... ligament in her left knee. Lady’s owner Hannah sought the help of Dr Jeff ... surgeon, to repair her cruciate ligament and help with the pain of Lady’s arthritis. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, ... executives and entrepreneurs, held The Future of San Diego Life Science event at the ... life science community attended the event with speakers Dr. Rich Heyman, former CEO of ...
(Date:5/23/2016)... May 23, 2016 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2016. The cash dividend of ... 29, 2016 to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):